Full Press Release Details
Reports Second Quarter 2023 Financial Results and
Reiterates Upcoming Milestones
rapid pace of enrollment with ~75% of expected patients now enrolled
ongoing potentially pivotal study evaluating Berubicin for the treatment of GBM
data from interim analysis from ongoing Berubicin potentially pivotal
on track before year end
HOUSTON, TX (August 14, 2023) - CNS Pharmaceuticals,
Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development
of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for
the quarter ended June 30, 2023, provided a corporate update and reiterates upcoming milestones.
"We are approaching the most important milestone
to date since we launched CNS Pharma. We are just a few months away from reporting topline results from our Berubicin potentially pivotal
study interim analysis and, although we do not know what the data looks like at this time, we remain hopeful as we also approach full
enrollment of the trial," commented John Climaco, CEO of CNS Pharmaceuticals. "Looking ahead, we remain focused on executing
on all of our operational efforts and importantly, taking our Berubicin trial for GBM across the finish line. We are poised for an exciting
remainder of the year with significant milestones anticipated in the near term and look forward to optimizing our opportunities to build
value for all shareholders in the near and long-term."
Recent Clinical Achievements
| Presented updated results from the on-going potentially pivotal study evaluating Berubicin in a poster presentation at the 2023 SNO/ASCO CNS Cancer Conference. | ||
| Announced enrollment of 180 patients; The Company has opened 46 clinical trial sites of the 60 sites selected across the U.S., Italy, France, Spain, and Switzerland. | ||
| Announced that the Company has reached the criteria required by the study protocol to conduct a pre-planned, non-binding futility analysis, which an independent Data Safety Monitoring Board will review to determine whether to recommend continuing the study as planned based on Berubicin showing potential value as a second-line treatment for patients with glioblastoma (GBM). | ||
| Pace of enrollment is rapidly accelerating with the first 75 patients taking 18 months to enroll while the second 75 patients took less than 6 months to enroll. |
Recent Corporate Achievements
Upcoming Expected Milestones for Potentially Pivotal Trial of
Berubicin for GBM, in the order expected:
| Achieve enrollment of 200 th patient in Q3 2023. | ||
| Report topline results of interim analysis expected in Q4 2023. | ||
| Complete enrollment in Q4 2023. |
Summary of Financial Results for the Second Quarter 2023
The net loss for the three months ended June 30,
2023 was approximately $4.0 million compared to approximately $3.6 million for the comparable period in 2022. The change in net loss is
attributable to an increase in research organization (CRO) expenses related to continued progress with the Company's clinical trial,
a credit to research and development expense in the prior year period for the funds collected from WPD Pharmaceuticals related to their
purchase of Berubicin drug product for their clinical trials, as well as increases in legal and professional fees and other expenses.
The Company reported research and development
expenses of $2.8 million for the three months ended June 30, 2023 compared to approximately $2.2 million for the comparable period in
2022. The increase in research and development expenses during the period were mainly attributed to the timing of CRO expenses related
to continued progress with the Company's clinical trial.
General and administrative expense was approximately
$1.2 million for the three months ended June 30, 2023 compared to approximately $1.3 million for the comparable period in 2022. The decrease
in general and administrative expense was mainly attributable to decreases of approximately $176,000 for employee compensation and taxes,
$100,000 in legal and professional expenses, $22,000 in insurance expenses and $12,000 in other expenses, which were offset by increases
of approximately $60,000 in marketing and advertising, $24,000 in board compensation and $39,000 in travel expenses.
As of June 30, 2023, the Company had cash of approximately
$4.3 million and working capital of approximately $2.1 million. The Company's current expectation is that the cash on hand is sufficient
to fund operations into the fourth quarter of 2023, through the topline data readout for the Berubicin potentially pivotal study. The
timing and costs of clinical trials are difficult to predict and trial plans and timing of milestones may change in response to evolving
circumstances and as such the foregoing estimates may prove to be inaccurate.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical
company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central
nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross
the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications
including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com,
and connect with the Company on Twitter, Facebook, and LinkedIn.
Forward-Looking Statements
Some of the statements in this press release are
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in
this press release include, without limitation, the Company's timing of the interim analysis to occur in the fourth quarter of 2023,
the ability to continue to open additional clinical trial sites on a timely basis, and the Company's projected cash runway. These
statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such
forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results
expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including
''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,''
''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking
statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including those
discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the Securities and Exchange Commission
("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking
statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements
contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated
Investor Relations Contact